Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients? Quality-Adjusted Time Without Symptoms or Toxicity

Comment

A Messori et al. J Clin Oncol. 1998 Nov.

. 1998 Nov;16(11):3716-7; author reply 3718.

doi: 10.1200/JCO.1998.16.11.3716.

No abstract available

Comment on

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Goldhirsch A, et al. J Clin Oncol. 1989 Jan;7(1):36-44. doi: 10.1200/JCO.1989.7.1.36. J Clin Oncol. 1989. PMID: 2642538 Clinical Trial.
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Cole BF, et al. J Clin Oncol. 1996 Oct;14(10):2666-73. doi: 10.1200/JCO.1996.14.10.2666. J Clin Oncol. 1996. PMID: 8874325 Clinical Trial.
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J. Zee B, et al. J Clin Oncol. 1998 Aug;16(8):2834-9. doi: 10.1200/JCO.1998.16.8.2834. J Clin Oncol. 1998. PMID: 9704736